JP2005520519A5 - - Google Patents

Download PDF

Info

Publication number
JP2005520519A5
JP2005520519A5 JP2003576613A JP2003576613A JP2005520519A5 JP 2005520519 A5 JP2005520519 A5 JP 2005520519A5 JP 2003576613 A JP2003576613 A JP 2003576613A JP 2003576613 A JP2003576613 A JP 2003576613A JP 2005520519 A5 JP2005520519 A5 JP 2005520519A5
Authority
JP
Japan
Prior art keywords
meganuclease
domain
derived
dodecapeptide
hybrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003576613A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005520519A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/001352 external-priority patent/WO2003078619A1/en
Publication of JP2005520519A publication Critical patent/JP2005520519A/ja
Publication of JP2005520519A5 publication Critical patent/JP2005520519A5/ja
Pending legal-status Critical Current

Links

JP2003576613A 2002-03-15 2003-03-14 ハイブリッドおよび単鎖メガヌクレアーゼならびにその使用 Pending JP2005520519A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36411302P 2002-03-15 2002-03-15
PCT/IB2003/001352 WO2003078619A1 (en) 2002-03-15 2003-03-14 Hybrid and single chain meganucleases and use thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2010102432A Division JP2010207234A (ja) 2002-03-15 2010-04-27 ハイブリッドおよび単鎖メガヌクレアーゼならびにその使用
JP2011136315A Division JP2011188867A (ja) 2002-03-15 2011-06-20 ハイブリッドおよび単鎖メガヌクレアーゼならびにその使用

Publications (2)

Publication Number Publication Date
JP2005520519A JP2005520519A (ja) 2005-07-14
JP2005520519A5 true JP2005520519A5 (OSRAM) 2006-04-13

Family

ID=28041871

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003576613A Pending JP2005520519A (ja) 2002-03-15 2003-03-14 ハイブリッドおよび単鎖メガヌクレアーゼならびにその使用
JP2010102432A Pending JP2010207234A (ja) 2002-03-15 2010-04-27 ハイブリッドおよび単鎖メガヌクレアーゼならびにその使用
JP2011136315A Pending JP2011188867A (ja) 2002-03-15 2011-06-20 ハイブリッドおよび単鎖メガヌクレアーゼならびにその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010102432A Pending JP2010207234A (ja) 2002-03-15 2010-04-27 ハイブリッドおよび単鎖メガヌクレアーゼならびにその使用
JP2011136315A Pending JP2011188867A (ja) 2002-03-15 2011-06-20 ハイブリッドおよび単鎖メガヌクレアーゼならびにその使用

Country Status (10)

Country Link
US (2) US8206965B2 (OSRAM)
EP (1) EP1485475B2 (OSRAM)
JP (3) JP2005520519A (OSRAM)
AT (1) ATE372379T1 (OSRAM)
AU (1) AU2003215869B2 (OSRAM)
CA (1) CA2479153C (OSRAM)
DE (1) DE60316124T3 (OSRAM)
DK (1) DK1485475T3 (OSRAM)
ES (1) ES2292994T3 (OSRAM)
WO (1) WO2003078619A1 (OSRAM)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003215869B2 (en) 2002-03-15 2008-04-24 Cellectis Hybrid and single chain meganucleases and use thereof
WO2009095742A1 (en) * 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
US20100151556A1 (en) * 2002-03-15 2010-06-17 Cellectis Hybrid and single chain meganucleases and use thereof
AU2004208031B2 (en) 2003-01-28 2009-10-08 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
EP1591521A1 (en) * 2004-04-30 2005-11-02 Cellectis I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
WO2007034262A1 (en) * 2005-09-19 2007-03-29 Cellectis Heterodimeric meganucleases and use thereof
AU2006224248B2 (en) 2005-03-15 2011-01-06 Cellectis I-Crei meganuclease variants with modified specificity, method of preparation and uses thereof
WO2007014275A2 (en) 2005-07-26 2007-02-01 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
EP2650366B1 (en) 2005-10-18 2017-03-22 Precision Biosciences Rationally designed meganucleases with altered sequence specificity and DNA-binding affinity
WO2007049095A1 (en) 2005-10-25 2007-05-03 Cellectis Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof
WO2007060495A1 (en) 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
WO2008010009A1 (en) * 2006-07-18 2008-01-24 Cellectis Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof
WO2008093152A1 (en) * 2007-02-01 2008-08-07 Cellectis Obligate heterodimer meganucleases and uses thereof
CA2688834C (en) 2007-06-01 2020-01-07 Ronald Buelow Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
EP2770052A1 (en) 2007-06-06 2014-08-27 Cellectis Method for enhancing the cleavage activity of I-CreI derived meganucleases
WO2008149176A1 (en) * 2007-06-06 2008-12-11 Cellectis Meganuclease variants cleaving a dna target sequence from the mouse rosa26 locus and uses thereof
BRPI0816750A2 (pt) 2007-06-29 2015-09-29 Pioneer Hi Bred Int métodos para alterar o genoma de uma célula de planta monocotiledônea e para modificar uma sequência alvo genômica endógena específica e planta de milho
WO2009013559A1 (en) 2007-07-23 2009-01-29 Cellectis Meganuclease variants cleaving a dna target sequence from the human hemoglobin beta gene and uses thereof
WO2009019528A1 (en) * 2007-08-03 2009-02-12 Cellectis Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof
EP2188384B1 (en) * 2007-09-27 2015-07-15 Sangamo BioSciences, Inc. Rapid in vivo identification of biologically active nucleases
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
AU2015201270B2 (en) * 2007-10-31 2017-01-19 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
EP2215223B1 (en) * 2007-10-31 2013-05-01 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
EP2215252A4 (en) * 2007-12-07 2011-01-26 Prec Biosciences Inc RATIONAL-DESIGNED MEGANUCLEASES WITH DETECTION SEQUENCES FROM DNASE-HYPERSENSITIVE REGIONS OF THE HUMAN GENOME
WO2009074842A1 (en) * 2007-12-13 2009-06-18 Cellectis Improved chimeric meganuclease enzymes and uses thereof
WO2009114321A2 (en) * 2008-03-11 2009-09-17 Precision Biosciencs, Inc. Rationally-designed meganucleases for maize genome engineering
US20100071083A1 (en) * 2008-03-12 2010-03-18 Smith James J Temperature-dependent meganuclease activity
AU2009241351A1 (en) * 2008-04-28 2009-11-05 Precision Biosciences, Inc. Fusion molecules of rationally-designed DNA-binding proteins and effector domains
DK2313498T3 (en) 2008-07-14 2017-05-22 Prec Biosciences Inc RECOGNITION SEQUENCES FOR I-CREI-DERIVED MECHANUCLEASES AND APPLICATIONS THEREOF
EP2352821B1 (en) * 2008-09-08 2016-11-23 Cellectis Meganuclease variants cleaving a dna target sequence from a glutamine synthetase gene and uses thereof
EP2180058A1 (en) 2008-10-23 2010-04-28 Cellectis Meganuclease recombination system
EP2208785A1 (en) 2009-01-15 2010-07-21 Newbiotechnic, S.A. Methods and kits to generate miRNA- and smallRNA-expressing vectors, and its application to develop lentiviral expression libraries
WO2010093966A2 (en) * 2009-02-12 2010-08-19 Fred Hutchinson Cancer Research Center Generation of a dna nicking enzyme that stimulates site-specific gene conversion from a homing endonuclease
WO2010107493A2 (en) 2009-03-20 2010-09-23 Sangamo Biosciences, Inc. Modification of cxcr4 using engineered zinc finger proteins
WO2010122367A2 (en) * 2009-04-21 2010-10-28 Cellectis Meganuclease variants cleaving the genomic insertion of a virus and uses thereof
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
US20120171191A1 (en) 2009-05-26 2012-07-05 Cellectis Meganuclease variants cleaving the genome of a pathogenic non-integrating virus and uses thereof
WO2011002503A1 (en) 2009-06-30 2011-01-06 Sangamo Biosciences, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
WO2011007193A1 (en) 2009-07-17 2011-01-20 Cellectis Viral vectors encoding a dna repair matrix and containing a virion-associated site specific meganuclease for gene targeting
CA2769262C (en) 2009-07-28 2019-04-30 Sangamo Biosciences, Inc. Methods and compositions for treating trinucleotide repeat disorders
EP3156504B1 (en) * 2009-08-11 2018-10-31 Sangamo Therapeutics, Inc. Organisms homozygous for targeted modification
WO2011021062A1 (en) 2009-08-21 2011-02-24 Cellectis Meganuclease variants cleaving a dna target sequence from the human lysosomal acid alpha-glucosidase gene and uses thereof
WO2011036640A2 (en) 2009-09-24 2011-03-31 Cellectis Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
EP2504429B1 (en) 2009-11-27 2016-04-20 BASF Plant Science Company GmbH Chimeric endonucleases and uses thereof
JP2013511979A (ja) 2009-11-27 2013-04-11 ビーエーエスエフ プラント サイエンス カンパニー ゲーエムベーハー キメラエンドヌクレアーゼおよびその使用
US8704041B2 (en) 2009-12-30 2014-04-22 Pioneer Hi Bred International Inc Methods and compositions for targeted polynucleotide modification
WO2011095475A1 (en) * 2010-02-02 2011-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and therapy of retinitis pigmentosa
WO2011101696A1 (en) 2010-02-18 2011-08-25 Cellectis Improved meganuclease recombination system
EP2539445B1 (en) 2010-02-26 2018-03-21 Cellectis Use of endonucleases for inserting transgenes into safe harbor loci
WO2011117249A1 (en) 2010-03-22 2011-09-29 Philip Morris Products S.A. Modifying enzyme activity in plants
EP2569435A1 (en) 2010-05-12 2013-03-20 Cellectis Meganuclease variants cleaving a dna target sequence from the rhodopsin gene and uses thereof
EP2569424A1 (en) 2010-05-12 2013-03-20 Cellectis Meganuclease variants cleaving a dna target sequence from the dystrophin gene and uses thereof
EP3156062A1 (en) 2010-05-17 2017-04-19 Sangamo BioSciences, Inc. Novel dna-binding proteins and uses thereof
WO2012001527A2 (en) 2010-06-15 2012-01-05 Cellectis S.A. Method for improving cleavage of dna by endonuclease sensitive to methylation
JP2013534423A (ja) 2010-07-07 2013-09-05 セレクティス Ｎａｎｏｇ遺伝子中のｄｎａ標的配列を切断するメガヌクレアーゼバリアント及びその使用
WO2012010976A2 (en) 2010-07-15 2012-01-26 Cellectis Meganuclease variants cleaving a dna target sequence in the tert gene and uses thereof
WO2012007848A2 (en) 2010-07-16 2012-01-19 Cellectis Meganuclease variants cleaving a dna target sequence in the was gene and uses thereof
AU2011287293B2 (en) 2010-08-02 2015-02-26 Cellectis S.A. Method for targeted genomic events in algae
EP2633040B1 (en) 2010-10-27 2019-07-10 Cellectis Method for increasing the efficiency of double-strand break-induced mutagenesis
US9044492B2 (en) 2011-02-04 2015-06-02 Cellectis Sa Method for modulating the efficiency of double-strand break-induced mutagenesis
EP2689019A2 (en) 2011-03-23 2014-01-29 Pioneer Hi-Bred International Inc. Methods for producing a complex transgenic trait locus
JP5996630B2 (ja) 2011-04-05 2016-09-21 セレクティスＣｅｌｌｅｃｔｉｓ コンパクトｔａｌｅ−ヌクレアーゼを作製する方法及びその使用
WO2012138901A1 (en) 2011-04-05 2012-10-11 Cellectis Sa Method for enhancing rare-cutting endonuclease efficiency and uses thereof
WO2012149470A1 (en) 2011-04-27 2012-11-01 Amyris, Inc. Methods for genomic modification
WO2012158778A1 (en) 2011-05-16 2012-11-22 Cellectis S.A. Doubly secure transgenic algae or cyanobacteria strains to prevent their establishment and spread in natural ecosystems
US9758796B2 (en) 2011-06-10 2017-09-12 Basf Plant Science Company Gmbh Nuclease fusion protein and uses thereof
AR086995A1 (es) 2011-06-21 2014-02-05 Pioneer Hi Bred Int Metodos y composiciones para producir plantas con esterilidad masculina
EP2729567B1 (en) 2011-07-08 2016-10-05 Cellectis Method for increasing the efficiency of double-strand break-induced mutagenssis
US9951346B2 (en) 2011-08-03 2018-04-24 Pioneer Hi-Bred International, Inc. Methods and compositions for targeted integration in a plant
NZ629427A (en) 2012-02-29 2016-04-29 Sangamo Biosciences Inc Methods and compositions for treating huntington’s disease
BR112014027468A2 (pt) 2012-05-04 2017-06-27 Du Pont polinucleotídeo isolado ou recombinante, construção de dna recombinante, célula, planta, explante vegetal, semente transgênica, polipeptídeo isolado, composição, métodos de produção de meganuclease, de introdução de rompimento e de integração de um polinucleotídeo.
US20140230083A1 (en) 2012-07-24 2014-08-14 Cellectis Modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins
EP3763810A3 (en) 2012-10-10 2021-07-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
US20160272980A1 (en) 2012-11-16 2016-09-22 Total Marketing Services Method for targeted modification of algae genomes
WO2014102688A1 (en) 2012-12-27 2014-07-03 Cellectis New design matrix for improvement of homology-directed gene targeting
US20140235933A1 (en) 2013-02-20 2014-08-21 Regeneron Pharmaceuticals, Inc. Genetic modification of rats
UA123532C2 (uk) 2013-03-12 2021-04-21 Е. І. Дю Пон Де Немур Енд Компані Спосіб ідентифікації варіантного сайта розпізнавання для сконструйованого засобу, що рідко розщеплює, для індукції двониткового розриву
KR102391734B1 (ko) 2013-03-15 2022-04-29 인3바이오 리미티드 자기조립형 합성 단백질
DK2986729T3 (en) 2013-04-16 2018-10-29 Regeneron Pharma TARGETED MODIFICATION OF ROOT THROUGH
AU2014346424B2 (en) 2013-11-11 2020-09-17 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's Disease
WO2015088643A1 (en) 2013-12-11 2015-06-18 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
PT3080279T (pt) 2013-12-11 2018-12-17 Regeneron Pharma Métodos e composições para a modificação direcionada de um genoma
AU2014368982B2 (en) 2013-12-19 2021-03-25 Amyris, Inc. Methods for genomic integration
AU2014368892B2 (en) 2013-12-20 2019-06-13 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
JP6594891B2 (ja) 2014-03-18 2019-10-23 サンガモ セラピューティクス， インコーポレイテッド ジンクフィンガータンパク質発現を調節するための方法および組成物
RU2704283C9 (ru) 2014-06-06 2020-02-07 Регенерон Фармасьютикалз, Инк. Способы и композиции для модификации целевого локуса
RS60366B1 (sr) 2014-06-23 2020-07-31 Regeneron Pharma Sastavljanje dnk posredovano nukleazom
PT3161128T (pt) 2014-06-26 2018-11-21 Regeneron Pharma Métodos e composições para modificações genéticas alvejadas e métodos de utilização
SG11201702309RA (en) 2014-10-15 2017-04-27 Regeneron Pharma Methods and compositions for generating or maintaining pluripotent cells
BR112017013104A2 (en) 2014-12-19 2018-05-15 Regeneron Pharmaceuticals, Inc. methods for modifying a target genomic locus in a cell, for enhancing homologous recombination at a target genomic locus in a cell, and for producing an f0 generation from a nonhuman animal.
WO2016161446A1 (en) 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
WO2016176652A2 (en) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
ES2983043T3 (es) 2015-12-18 2024-10-21 Sangamo Therapeutics Inc Alteración dirigida del receptor de células T
AU2016374253B2 (en) 2015-12-18 2021-10-21 Sangamo Therapeutics, Inc. Targeted disruption of the MHC cell receptor
US11293033B2 (en) 2016-05-18 2022-04-05 Amyris, Inc. Compositions and methods for genomic integration of nucleic acids into exogenous landing pads
KR20190041476A (ko) 2016-07-29 2019-04-22 리제너론 파마슈티칼스 인코포레이티드 C-절단된 피브릴린-1의 발현을 유도하는 돌연변이를 포함하는 마우스
IL300783B2 (en) 2016-08-24 2026-03-01 Sangamo Therapeutics Inc Engineered nucleases with target-specific zinc fingers
MX2019003176A (es) 2016-09-23 2019-07-04 Hutchinson Fred Cancer Res Receptores de linfocitos t (tcr) especificos del antigeno menor de histocompatibilidad (h) ah-1 y sus usos.
US12016313B2 (en) 2017-01-19 2024-06-25 Omniab Operations, Inc. Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
EP3595708A4 (en) 2017-03-15 2020-12-16 Fred Hutchinson Cancer Research Center HIGH AFFINITY MAGE-A1 SPECIFIC TCRS AND THEIR USES
ES2981244T3 (es) 2017-04-28 2024-10-07 Acuitas Therapeutics Inc Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos
US11655275B2 (en) 2017-05-03 2023-05-23 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
CA3064000A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
US12398191B2 (en) 2017-08-11 2025-08-26 Fred Hutchinson Cancer Center BRAF-specific TCRs and uses thereof
FI3675623T3 (fi) 2017-08-29 2025-08-15 Kws Saat Se & Co Kgaa Parannettuja sinisiä aleuroni- ja muita segregaatiojärjestelmiä
CA3071661A1 (en) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center Strep-tag specific chimeric receptors and uses thereof
WO2019051135A1 (en) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center METHODS FOR IMPROVING ADOPTIVE CELL THERAPY
JP7139419B2 (ja) 2017-09-29 2022-09-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｔｔｒ遺伝子座を含む非ヒト動物および使用方法
EP3697435A1 (en) 2017-10-20 2020-08-26 Fred Hutchinson Cancer Research Center Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
WO2019109047A1 (en) 2017-12-01 2019-06-06 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
WO2019140278A1 (en) 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunotherapy targeting core binding factor antigens
EP3759130A1 (en) 2018-02-26 2021-01-06 Fred Hutchinson Cancer Research Center Compositions and methods for cellular immunotherapy
ES3036459T3 (en) 2018-03-12 2025-09-19 Pioneer Hi Bred Int Methods for plant transformation
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
KR20210049119A (ko) 2018-08-22 2021-05-04 프레드 헛친슨 켄서 리서치 센터 Kras 또는 her2 항원을 표적으로 하는 면역요법
BR112021003830A2 (pt) 2018-08-28 2021-07-20 Fred Hutchinson Cancer Research Center métodos e composições para terapia celular t adotiva incorporando sinalização notch induzida
AU2019344927A1 (en) 2018-09-18 2021-04-01 Sangamo Therapeutics, Inc. Programmed cell death 1 (PD1) specific nucleases
IL281615B2 (en) 2018-09-21 2026-01-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
US20240165232A1 (en) 2018-09-24 2024-05-23 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
US12583816B2 (en) 2018-10-18 2026-03-24 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
KR20210102231A (ko) 2018-11-09 2021-08-19 프레드 헛친슨 켄서 리서치 센터 메소텔린에 특이적인 t 세포 수용체 및 면역요법에서의 그의 용도
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
US11690362B2 (en) 2018-12-20 2023-07-04 Regeneran Pharmaceuticals, Inc. Nuclease-mediated repeat expansion
JP7523449B2 (ja) 2019-01-11 2024-07-26 アクイタス セラピューティクス インコーポレイテッド 活性剤の脂質ナノ粒子送達のための脂質
GB2596461B (en) 2019-02-20 2023-09-27 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
WO2020185796A1 (en) 2019-03-11 2020-09-17 Fred Hutchinson Cancer Research Center High avidity wt1 t cell receptors and uses thereof
ES2966625T3 (es) 2019-04-04 2024-04-23 Regeneron Pharma Roedores que comprenden un locus del factor de coagulación 12 humanizado
AU2020253531C1 (en) 2019-04-04 2022-06-16 Regeneron Pharmaceuticals, Inc. Methods for scarless introduction of targeted modifications into targeting vectors
US11891618B2 (en) 2019-06-04 2024-02-06 Regeneron Pharmaceuticals, Inc. Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
CA3137764A1 (en) 2019-06-07 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized albumin locus
AU2020334064A1 (en) 2019-08-20 2022-03-03 Fred Hutchinson Cancer Center T-cell immunotherapy specific for WT-1
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
JP7798855B2 (ja) 2020-07-16 2026-01-14 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子に使用するためのカチオン性脂質
EP4501951A3 (en) 2020-08-25 2025-04-30 Kite Pharma, Inc. T cells with improved functionality
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
CN116724053A (zh) 2020-09-24 2023-09-08 弗雷德哈钦森癌症中心 靶向sox2抗原的免疫治疗
TW202222841A (zh) 2020-10-06 2022-06-16 福瑞德哈金森腫瘤研究中心 用於治療表現mage-a1之疾病的組成物及方法
WO2022132836A2 (en) 2020-12-14 2022-06-23 Fred Hutchinson Cancer Research Center Compositions and methods for cellular immunotherapy
WO2022240846A1 (en) 2021-05-10 2022-11-17 Sqz Biotechnologies Company Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
JP2024520676A (ja) 2021-06-02 2024-05-24 ライエル・イミュノファーマ・インコーポレイテッド Ｎｒ４ａ３欠損免疫細胞及びその使用
US20250250319A1 (en) 2021-07-15 2025-08-07 Fred Hutchinson Cancer Center Chimeric transmembrane polypeptides comprising a tgf beta receptor extracellular domain, a transmembrane domain and an interleukin receptor 2 intracellular signalling domain and its use in therapy
US20250114452A1 (en) 2021-08-04 2025-04-10 The Regents Of The University Of Colorado, A Body Corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
IL311962A (en) 2021-10-14 2024-06-01 Lonza Sales Ag Modified producer cells for extracellular vesicle production
EP4426832A1 (en) 2021-11-03 2024-09-11 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Precise genome editing using retrons
CA3242402A1 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
EP4457342A1 (en) 2021-12-29 2024-11-06 Bristol-Myers Squibb Company Generation of landing pad cell lines
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
EP4522726A1 (en) 2022-05-09 2025-03-19 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
KR20250027283A (ko) 2022-05-19 2025-02-25 라이엘 이뮤노파마, 인크. nr4a3을 표적하는 폴리뉴클레오타이드 및 이의 용도
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2025054540A1 (en) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Methods of gene-editing using programmable nucleases
WO2025081123A1 (en) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Methods and compositions for improving t cell immunotherapy
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5006333A (en) * 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
FR2646438B1 (fr) * 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US6063630A (en) * 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5436150A (en) * 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US20040019916A1 (en) * 1992-04-24 2004-01-29 Zarling David A. In vivo homologous sequence targeting in eukaryotic cells
US5474896A (en) 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5792632A (en) * 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US6395959B1 (en) * 1992-05-05 2002-05-28 Institut Pasteur Nucleotide sequence encoding the enzyme I SceI and the use thereof
JPH08510375A (ja) 1993-02-12 1996-11-05 ザ・ジョンズ−ホプキンス・ユニバーシティー フラボバクテリウム・オケアノコイテス（ｆｏｋｉ）制限エンドヌクレアーゼの機能ドメイン
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
IL120241A0 (en) * 1997-02-17 1997-06-10 B G Negev Technologies And App DNA segments encoding a domain of ho-endonuclease
US6232112B1 (en) * 1997-11-24 2001-05-15 Flinders Technologies Pty Ltd Of Flinders University Reagents and methods for diversification of DNA
JP2002535995A (ja) 1999-02-03 2002-10-29 ザ チルドレンズ メディカル センター コーポレイション 染色体標的部位での二本鎖ｄｎａ切断の誘導を含む遺伝子修復
WO2000046385A1 (en) 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving in vivo excision of targeting dna
WO2002068471A2 (en) * 2000-12-21 2002-09-06 Bristol-Myers Squibb Company Nucleic acid molecules and polypeptides for a human cation channel polypeptide
DE10131786A1 (de) * 2001-07-04 2003-01-16 Sungene Gmbh & Co Kgaa Rekombinationssysteme und Verfahren zum Entfernen von Nukleinsäuresequenzen aus dem Genom eukaryotischer Organismen
US20030228583A1 (en) * 2001-10-31 2003-12-11 Amacher David E. Biomarkers of liver response
US7462758B2 (en) * 2001-12-20 2008-12-09 Sungene Gmbh & Co. Kgaa Methods for the transformation of vegetal plastids
AU2003215869B2 (en) * 2002-03-15 2008-04-24 Cellectis Hybrid and single chain meganucleases and use thereof
WO2009095742A1 (en) † 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
AU2004208031B2 (en) * 2003-01-28 2009-10-08 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
US7888121B2 (en) * 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP1591521A1 (en) * 2004-04-30 2005-11-02 Cellectis I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
EP2650366B1 (en) † 2005-10-18 2017-03-22 Precision Biosciences Rationally designed meganucleases with altered sequence specificity and DNA-binding affinity
BRPI0816750A2 (pt) † 2007-06-29 2015-09-29 Pioneer Hi Bred Int métodos para alterar o genoma de uma célula de planta monocotiledônea e para modificar uma sequência alvo genômica endógena específica e planta de milho
EP2215223B1 (en) † 2007-10-31 2013-05-01 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
WO2009074842A1 (en) † 2007-12-13 2009-06-18 Cellectis Improved chimeric meganuclease enzymes and uses thereof

Similar Documents

Publication Publication Date Title
Hafez et al. Homing endonucleases: DNA scissors on a mission
Doyle et al. TAL effectors: highly adaptable phytobacterial virulence factors and readily engineered DNA-targeting proteins
US10844378B2 (en) RNA-directed DNA cleavage by the Cas9-crRNA complex
AU2020223370B2 (en) Enzymes with RuvC domains
Pingoud Restriction endonucleases
US11124782B2 (en) Cas variants for gene editing
Aiba et al. Artificial DNA cutters for DNA manipulation and genome engineering
ES2346219T3 (es) Vectores plasmidicos de clonacion de adn y procedimiento para su uso.
ES2781323T3 (es) Montaje de ADN mediado por nucleasas
Kobayashi Behavior of restriction–modification systems as selfish mobile elements and their impact on genome evolution
JP4448619B2 (ja) 組換えポリヌクレオチド配列をＩｎｖｉｔｒｏで得る方法、配列バンク及びかくして得られた配列
Bujnicki Understanding the evolution of restriction-modification systems: clues from sequence and structure comparisons.
Mussolino et al. TALE nucleases: tailored genome engineering made easy
US20150056629A1 (en) Compositions, systems, and methods for detecting a DNA sequence
JP2006518372A5 (OSRAM)
WO2018013990A1 (en) Scarless dna assembly and genome editing using crispr/cpf1 and dna ligase
DE69833457D1 (de) Neuartige methode zur integration von fremd-dna ins eukaryotische genom
CA3177828A1 (en) Enzymes with ruvc domains
CA3049989A1 (en) A modular universal plasmid design strategy for the assembly and editing of multiple dna constructs for multiple hosts
DK1945762T3 (da) Rationelt konstruerede meganucleaser med ændret sekvensspecificitet og DNA-bindingsaffinitet
CN110106173A (zh) 改进的基因组编辑方法
JP2019500036A (ja) 原核生物におけるｄｎａ末端修復経路の再構築
Li et al. Nucleases in gene-editing technologies: past and prologue
CN105602972B (zh) 基于CRISPR-Cas9体外改造腺病毒载体的方法
Bigot et al. Characteristics of inteins in invertebrate iridoviruses and factors controlling insertion in their viral hosts